What are the best treatments for Acute myelogenous leukemia (AML)?

TL;DR: Treatment for Acute myelogenous leukemia (AML) typically involves intensive induction chemotherapy to induce remission, followed by consolidation therapy to prevent relapse. In many cases, particularly for high-risk patients, a hematopoietic stem cell transplant (HSCT) is the definitive therapeutic approach to achieve long-term survival.

What are the first-line treatments for Acute myelogenous leukemia (AML)?

The standard of care for Acute myelogenous leukemia (AML) begins with "induction" therapy, usually a combination of cytarabine and an anthracycline (such as daunorubicin or idarubicin). The goal is to destroy as many leukemia cells as possible to restore normal blood cell production. Once remission is achieved, "consolidation" therapy follows, which may involve high-dose chemotherapy or, for eligible patients, an allogeneic stem cell transplant to replace diseased marrow with healthy donor cells.

Which medications are commonly prescribed?

Treatment protocols for Acute myelogenous leukemia (AML) are increasingly personalized based on genetic mutations. Common medications include:

• Cytarabine: The backbone of most Acute myelogenous leukemia (AML) regimens.


• Anthracyclines: Such as daunorubicin (Cerubidine) or idarubicin (Idamycin).


• Targeted therapies: Midostaurin (Rydapt) for FLT3-mutated disease, or venetoclax (Venclexta) combined with hypomethylating agents for patients unable to tolerate intensive chemotherapy.


• Enasidenib (Idhifa) or Ivosidenib (Tibsovo): Used for specific IDH-mutated variants of the disease.

What is the multidisciplinary approach to care?

Managing Acute myelogenous leukemia (AML) requires a specialized team. Key specialists include:

• Hematologist-Oncologists: To lead the primary treatment strategy.


• Transplant specialists: If HSCT is required.


• Infectious disease experts: To manage the high risk of infection during periods of neutropenia.


• Clinical psychologists: To support the significant emotional burden of an Acute myelogenous leukemia (AML) diagnosis.


• Physical and occupational therapists: To maintain strength and independence during lengthy hospitalizations.

How does treatment effectiveness vary?

Effectiveness in Acute myelogenous leukemia (AML) varies significantly based on age, performance status, and specific cytogenetic or molecular markers (such as NPM1, FLT3, or CEBPA mutations). While 62 members of our DiseaseMaps.org community have shared their unique journeys, clinical outcomes are highly individualized, and prognosis should be discussed directly with your oncology team.

Next steps

• Consult with a board-certified hematologist-oncologist specializing in leukemia.


• Ask your doctor about biomarker testing to see if you are a candidate for targeted clinical trials.


• Connect with the DiseaseMaps.org community to share experiences with others managing this condition.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your primary oncology team for personalized treatment decisions.

References

• NIH National Cancer Institute (NCI) - AML Treatment Overview


• American Cancer Society (ACS) - Acute Myeloid Leukemia (AML)


• Leukemia & Lymphoma Society (LLS) - Treatment Protocols


• Orphanet - Rare Disease Database